Tyrosine News and Research

RSS

Second-quarter fiscal 2010 results announced by Pharmacyclics

Pharmacyclics, Inc. today reported financial results for its second fiscal quarter ended December 31, 2009.

12 Feb 2010

Clarient launches Clarient Insight Dx Pulmotype Test for lung cancer

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new lung cancer test, Clarient Insight® Dx Pulmotype® Test, that helps physicians classify specific types of lung cancer to identify which therapies may be most effective.

10 Feb 2010

QIAGEN acquires global licence for PI3K gene to develop real-time-PCR and endpoint PCR assays

QIAGEN today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays.

From QIAGEN Manchester Limited 8 Feb 2010

Sermo announces a new report on evolving trends in CML

Sermo, the world's largest online community for physicians, today announced a Sermo Event™ Report titled "Evolving Trends in CML." The new report measures the impact of ENESTnd trial data on Oncologists' use of Tasigna (Novartis), Sprycel (Bristol Myers-Squibb) and Gleevec (Novartis) in newly diagnosed CML patients and assesses overall trends in CML monitoring and management. While Gleevec will likely remain the #1 treatment, there will be a close race for the runner-up spot amongst second-generation tyrosine kinase inhibitors in the front line setting.

4 Feb 2010

Study sheds light on pancreatic cancer development and new potential drug targets

Researchers at the Moores Cancer Center at the University of California, San Diego, have found one reason that pancreatic cancer tumors are so difficult to treat with drugs. They have shown how a molecular switch steps up pancreatic cancer cell survival as well as resistance to a standard chemotherapy drug, and have identified alternate routes cancer cells take to avoid the effects of the therapy.

29 Jan 2010

Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced

4SC AG, a drug discovery and development company, today announced the start of dosing in a First-in-Man Phase I study in healthy volunteers evaluating 4SC-203, a novel multi-target kinase inhibitor, with particular specificity against selected kinases, including FMS-like tyrosine kinase 3 (FLT3), FLT3 mutants and vascular endothelial growth factor receptors (VEGF-R).

21 Jan 2010

Combination treatment strategies may benefit patients with non-small cell lung cancer

Even when their tumors are shrinking in response to therapy, some non-small cell lung cancer (NSCLC) patients have a scattering of cancer cells that are undeterred by the drug, causing the tumor to resume its growth, Dana-Farber Cancer Institute and Massachusetts General Hospital (MGH) Cancer Center scientists report in the January issue of Cancer Cell.

20 Jan 2010

AstraZeneca and Dako Denmark A/S enter into collaboration agreement

AstraZeneca and Dako Denmark A/S announced today that they have entered into a collaboration agreement to develop companion diagnostic tests for multiple AstraZeneca oncology projects, including biologics and small molecules, in various stages of discovery and development.

18 Jan 2010

Ambit Biosciences and Astellas Pharma to jointly develop and commercialize FLT3 kinase inhibitors

Ambit Biosciences Corporation and Astellas Pharma Inc. today announced that they have entered into a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications.

18 Dec 2009

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Ambit Biosciences Corporation announced today the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid leukemia (AML).

11 Dec 2009

Mouse model may help identify unknown mutations that make lung cancer cells resistant to therapy

Lung cancer is the leading cause of cancer mortality worldwide and lung adenocarcinoma is the most common type. Many cases of lung adenocarcinoma are attributed to a mutation in a gene for the epidermal growth factor receptor (EGFR).

9 Dec 2009

CML patients on nilotinib or dasatinib drug achieve better response than imatinib drug

Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients

ARIAD Pharmaceuticals, Inc. today announced positive clinical data from an ongoing Phase 1 study of its investigational, pan-BCR-ABL inhibitor, AP24534, in patients with advanced hematological cancers.

8 Dec 2009

Ambit Biosciences presents study results of its AC220 FLT3 inhibitor for AML

Ambit Biosciences Corporation announced today that preliminary results from a clinical trial of its lead product candidate, AC220, in acute myeloid leukemia (AML) were presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans. AC220 is a novel, orally available, small molecule that was expressly optimized as a FMS-like tyrosine kinase-3 (FLT3) inhibitor for the treatment of AML.

8 Dec 2009

Phase II clinical trial results reveal positive effects of omacetaxine against CML

Results from a phase II clinical trial indicate a novel drug may provide a treatment option for chronic myeloid leukemia (CML) patients who do not respond to current therapies, researchers from The University of Texas M. D. Anderson Cancer Center report today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting

Ambit Biosciences Corporation announced today the presentation of two posters presenting the results of preclinical studies evaluating AC220 at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans.

8 Dec 2009

New treatment options for leukemia and myeloproliferative disorders introduced

Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology introduces potential new treatment options and improved diagnostic methods for patients suffering from acute promyelocytic leukemia, chronic myeloid leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that are based on a better understanding of the underlying genetic causes of these conditions.

6 Dec 2009

Pre-clinical study data of Stemline Therapeutics' IL-3R targeting agents to be presented at the ASH meeting

Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chronic myeloid leukemia (CML) have been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009.

4 Dec 2009

Preclinical data of Curis' HSP 90 inhibitor published

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that preclinical data related to CUDC-305, the company’s Heat Shock Protein (HSP) 90 inhibitor, was published online this week in Molecular Cancer Therapeutics.

4 Dec 2009

ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro

ChemGenex Pharmaceuticals Limited announced today that updated clinical data from several of its clinical trials with Omapro™ (omacetaxine mepesuccinate) will be presented at the upcoming 51st American Society of Hematology Annual Meeting in New Orleans, Louisiana.

1 Dec 2009

Tyrosine News and Research

Second-quarter fiscal 2010 results announced by Pharmacyclics

Clarient launches Clarient Insight Dx Pulmotype Test for lung cancer

QIAGEN acquires global licence for PI3K gene to develop real-time-PCR and endpoint PCR assays

Sermo announces a new report on evolving trends in CML

Study sheds light on pancreatic cancer development and new potential drug targets

Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced

Combination treatment strategies may benefit patients with non-small cell lung cancer

AstraZeneca and Dako Denmark A/S enter into collaboration agreement

Ambit Biosciences and Astellas Pharma to jointly develop and commercialize FLT3 kinase inhibitors

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Mouse model may help identify unknown mutations that make lung cancer cells resistant to therapy

CML patients on nilotinib or dasatinib drug achieve better response than imatinib drug

Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients

Ambit Biosciences presents study results of its AC220 FLT3 inhibitor for AML

Phase II clinical trial results reveal positive effects of omacetaxine against CML

Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting

New treatment options for leukemia and myeloproliferative disorders introduced

Pre-clinical study data of Stemline Therapeutics' IL-3R targeting agents to be presented at the ASH meeting

Preclinical data of Curis' HSP 90 inhibitor published

ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News